Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Assess the Efficacy and Safety of Trastuzumab in Combination With Xelox as First-line Treatment of Patients With Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction, (HER2)-Positive.

NCT01503983 is registered in ClinicalTrials.gov with Fundación para el Progreso de la Oncología en Cantabria as lead sponsor.

NCT NCT01503983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01503983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Assess the Efficacy and Safety of Trastuzumab in Combination With Xelox as First-line Treatment of Patients With Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction, (HER2)-Positive.
Lead sponsor
Fundación para el Progreso de la Oncología en Cantabria
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
May 31, 2015
Enrollment
45 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv gastric cancer with metastasis